Related Experiment Video

Updated: May 22, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

Anticoagulation in children

Paul Monagle1, Fiona Newall

  • 1Department of Clinical Haematology, Royal Children's Hospital, Melbourne, Victoria, Australia.

Thrombosis Research
|April 25, 2012
PubMed

Insights

Anticoagulation therapy in children, including neonates, is increasing. This review focuses on managing complex patient groups and clinical situations, highlighting research needs in pediatric anticoagulation.

Area of Science:

  • Pediatric Pharmacology
  • Hematology
  • Clinical Pediatrics

Background:

  • Increasing use of anticoagulation therapy in neonates and children.
  • Existing reviews often focus on anticoagulant agents and monitoring.
  • Need for a different perspective on pediatric anticoagulation challenges.

Purpose of the Study:

  • To address complexities of anticoagulation in specific pediatric populations.
  • To examine challenges in particular clinical situations requiring anticoagulation in children.
  • To identify research gaps in managing pediatric anticoagulation.

Main Methods:

  • Review of current literature on pediatric anticoagulation.
  • Focus on specific patient groups: neonates and adolescents.
  • Analysis of clinical scenarios: pediatric cancer and invasive procedures.

Main Results:

  • Identified challenges in anticoagulating neonates and adolescents.
  • Highlighted complexities in managing anticoagulation during pediatric cancer treatment.
  • Discussed difficulties in anticoagulation for children undergoing invasive procedures.

Conclusions:

  • Significant research is needed for optimal anticoagulation management in diverse pediatric populations.
  • Further investigation required for specific clinical situations involving pediatric anticoagulation.
  • Understanding anticoagulant interactions in pediatric plasma remains crucial.

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...